Ultreon™ 1.0 Software

Experience the Power of Automation

Ultreon 1.0 Software has step-by-step guidance to streamline the use of OCT intravascular imaging and RFR/FFR, prioritizing ease of use for interventional cardiologists (ICs)

Go Beyond the Limitations of Angiography with OCT Imaging

Ultreon™ 1.0 Software is the intravascular imaging and coronary physiology software on one platform to guide percutaneous coronary intervention (PCI). Ultreon™ 1.0 Software is developed for Optical Coherence Tomography (OCT), used with OPTIS™ Next Imaging Systems.

Streamlined and intuitive, Ultreon™ 1.0 Software gives better insights to optimize patient outcomes through automation and an improved workflow.1-4

Performing PCI based on coronary angiography alone is inadequate for determining key metrics of the vessel such as the extent of coronary artery disease, plaque distribution and composition, and dimensions.5 Ultreon™ Software for OCT allows interventional cardiologists to see inside the heart during PCI and act on the obtained insights.

OCT is an imaging modality that uses near-infrared light to provide high-definition images of the artery with high precision allowing to assess lesion characteristics and plaque morphology for coronary artery disease.

  • Ultreon™ Software helps to guide physicians through PCI step-by-step following MLD MAX workflow and provides insights on morphology, vessel sizing, stent placement and post-stent optimization for more accurate decision-making.6
  • Ultreon™ Software is powered by artificial intelligence (AI) that enables automatic quantification of calcification and vessel sizing.1

See Simply & Act Decisively During PCI with Ultreon 1.0 Software

See Simply

The Ultreon™ Software with an intuitive interface offers physicians user-friendly on-screen information and step-by-step guidance following MLD MAX workflow to aid with decision-making,6 to determine a proper treatment technique pre-PCI and to ensure optimal stent expansion results post-PCI.

Ultreon workflow interface

Ultreon™ 1.0 Software intuitive workflow interface - 1

Ultreon workflow interface

Ultreon™ 1.0 Software intuitive workflow interface - 2


Ultreon™ 1.0 Software uses artificial intelligence (AI) to automatically detect degree and thickness of calcification.1

  • Auto-detects and highlights calcification arc and max thickness7
  • Displays calcification angle and max thickness values throughout the pullback in real-time7
  • Highlights calcification overlays on the vessel with the co-registration view7

Watch how to use Ultreon™ 1.0 Software for morphology assessment

Morphology screen

Morphology screen displaying angle and max thickness of calcification


Ultreon™ 1.0 Software uses artificial intelligence (AI) to automatically detect external elastic lamina (EEL) and lumen to help identify landing zones for accurate stent placement.1,8

  • Provides vessel diameter measurements7
  • Facilitates measuring lesion length and identification of optimal user-adjusted stent landing zones on a single screen7
  • Autodetects and provides measurement of lumen and detectable external elastic lamina (EEL) for quick visualization7
  • Facilitates stent length selection through co-registration7

Watch how to use Ultreon™ 1.0 Software to determine stent sizing

Ultreon sizing screen

Sizing screen displaying External Elastic Lamina (EEL) for current frame and Lumen diameter for proximal, current and distal frames

"I do OCT in 95% of all my cases and the data-driven guided interface with ULTREON™ Software has ignited an imaging revolution, making imaging interpretation easier (through automatic EEL and calcium detection) and the supported guided-user interface."

– Dr. Jonathan Hill, London UK

Act Decisively


Ultreon™ Software provides side-by-side viewing of live and co-registered angio to help physicians guide precise stent deployment.7

  • Helps to ensure complete lesion coverage and avoid stent edges in high-risk morphology9


Watch how to use Ultreon™ 1.0 Software for stent deployment

Ultreon interface

Ultreon™ 1.0 Software interface for stent deployment


Ultreon™ Software helps to ensure optimal stent expansion and apposition with instantaneous display of expansion and apposition results.7

Watch how to use Ultreon™ 1.0 Software to optimize stent placement

 Ultreon interface

Ultreon™ 1.0 Software interface for review assessment

Watch OCT-Guided PCI Live Cases With Ultreon 1.0 Software

OCT-guided PCI Live Case: Calcified Lesion

In this PCI case of a calcified lesion, the expert panel discusses when to use physiology and when to use imaging during PCI, and how these tools can guide and support the procedure. During the case, the physicians use Ultreon™ Software that’s enabled by AI, to showcase its features such as automatic calcium detection, automatic EEL detection, live angio co-registration and more.

OCT-guided PCI Live Case: Long Diffuse LAD Lesion

In this complex PCI case of a long diffuse LAD lesion, the expert panel discusses how physiology and OCT imaging pre- and post-PCI can guide and support treatment. During the case, the physicians use PressureWire™ X Guidewire for physiology assessment and Ultreon™ Software that’s enabled by AI for intravascular imaging. Physicians showcase its features such as automatic calcium detection, automatic EEL detection, and how to perform PCI following MLD MAX workflow.

Ultreon 1.0 Software: The Next-Generation Imaging and Physiology Platform


  1. Data on file at Abbott.
  2. Zhang J, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ULTIMATE trial. J Am Coll Cardiol. 2018;72(24):3126-3137. doi: 10.1016/j.jacc.2018.09.013.
  3. Hong M, et al. IVUS-XPL 5 Year Outcomes, TCT 2019.
  4. Jones et al. JACC Cardiovascular Interventions, 2018, vol 11 (14). “Angiography Alone Versus Angiography Plus Optical Coherence Tomography to Guide Percutaneous Coronary Intervention – Outcomes From the Pan-London PCI Cohort”.
  5. Reyes, M. The next innovation in PCI is not a stent. The value of OCT. CathLab Digest. Oct 6, 2019. Volume 27, Issue 10.
  6. Bezerra H, et al. Analysis of changes in decision-making process during optical coherence tomography-guided percutaneous coronary interventions: Insights from the LightLab Intiative. EuroPCR 2020.
  7. Ultreon™ 1.0 Software IFU. Refer to Instructions For Use (IFU) for additional information.
  8. Prati, F. et al. The CLI-OPCI II Study. JACC: Cardiovascular Imaging, 2015: Vol 8, No. 11:1297-305.
  9. Kubo T, et al. Application of optical coherence tomography in percutaneous coronary intervention. Circ J. 2012;76(9):2076-2083. doi: 10.1253/circj.cj-12-0828.

MAT-2106678 v2.0

OPTIS™ Next Imaging Systems and Software


The Ultreon™ 1.0 Software is intended to be used only with compatible OPTIS™ Next Imaging Systems. The OPTIS™ Next Imaging System with a compatible Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is intended for use in vessels 2.0 to 3.5 mm in diameter. The Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is not intended for use in the left main coronary artery or in a target vessel which has undergone a previous bypass procedure. The OPTIS™ Next Imaging System is intended for use in the catheterization and related cardiovascular specialty laboratories and will further compute and display various physiological parameters based on the output from one or more electrodes, transducers, or measuring devices. The physician may use the acquired physiological parameters, along with knowledge of patient history, medical expertise, and clinical judgment to determine if therapeutic intervention is indicated.

Contraindications: Use of the Ultreon™ 1.0 Software is contraindicated where introduction of any catheter would constitute a threat to patient safety.
Contraindications include:

  • Bacteremia or sepsis
  • Major coagulation system abnormalities
  • Patients diagnosed with coronary artery spasm
  • Patients disqualified for coronary artery bypass graft (CABG) surgery
  • Patients disqualified for percutaneous transluminal coronary angioplasty (PTCA)
  • Severe hemodynamic instability or shock
  • Total occlusion
  • Large thrombus
  • Acute renal failure
  • Inability to tolerate systemic anticoagulation is a contraindication to use of OCT for coronary imaging.
  • PressureWire™ Guidewire is contraindicated for use in the cerebral vasculature.
  • The system has no patient alarm functions. Do not use for cardiac monitoring.


Complications: The risks involved in vascular imaging include those associated with all catheterization procedures. The following complications may occur as a consequence of intravascular imaging and may necessitate additional medical treatment including surgical intervention.

  • Abnormal heart rhythm or arrhythmias
  • Acute myocardial infarction
  • Allergic reaction to the contrast media or drug administered for the procedure
  • Arterial dissection, injury, or perforation
  • Bleeding
  • Catheter access site reactions: sterile inflammation or granuloma
  • Coronary artery spasm
  • Death
  • Embolism
  • Myocardial ischemia
  • Renal insufficiency or failure from contrast media use
  • Repeat revascularization
  • Thrombus formation, abrupt closure, or total occlusion
  • Tissue necrosis
  • Unstable angina
  • Hypotension


  • Refer to the contrast media Instructions for Use for general warnings and precautions relating to use of contrast media.
  • The heart rate and mean pressure values shown on the OPTIS™ Next Imaging System are for reference only and are not intended to be used as the primary display.
  • The system may place the point of index value at the wrong location due to pressure artifacts, for example: abnormal heartbeats, artifacts in AO (Pa) caused by flushing of guiding catheter, or valve opening / closing. The physician should always confirm that the point selected by the system is a valid point for the calculation of index value.
  • Inside the catheterization laboratory, only port-powered USB drives may be connected to the USB port. Connecting externally powered devices to the USB port in the patient vicinity may compromise electrical isolation and cause patient injury.
  • To protect the privacy and security of sensitive information, including electronic protected health information (EPHI), and to protect the integrity of the system itself, the system should be located in a physically secure, access-controlled environment. Do not use the OPTIS™ Next Imaging System if there is reason to believe the system’s security has been compromised or if the system was unaccounted for during a period of time (i.e., misappropriated, modified, or tampered with).


  • Safety and effectiveness have been established for the following patient population: adult patients undergoing non-emergent percutaneous coronary interventions in lesions with reference vessel diameters between 2.0 to 3.5 mm, which were not located in the left main coronary artery or in a target vessel which has undergone previous bypass procedures.
  • Monitor the OCT image for indications of Dragonfly™ Imaging Catheter optical failure. If optical failure is suspected, remove the Dragonfly™ Imaging Catheter from the patient, press “Unload” on the drive motor and optical controller (DOC), detach the catheter, and replace it with a new one.
  • If the pullback triggers before contrast is injected, repeat the pullback.
  • For optimal imaging, only use 100% contrast media.

MAT-2104193 v3.0